For example, ruxolitinib mitigates acute GVHD by reducing CXCR3 expression, which results in less T-cell infiltrates in target organs (59, 71, 72), and by decreasing IFN-γ and IL17A production in CD4+ T cells (73). Here, CD4 is linked to acute graft versus host disease.